Neurogene Inc.

Healthcare

NASDAQ:NGNE · NASDAQ Global Market

Market Cap $459.84M Beta 2.04 P/E (TTM) -6.6

$29.10 +0.34%

+$0.10 today

52W Low $14.65High $37.27

Vol 0.11M · Avg 0.16M

EPS (TTM)-$4.42

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+47.27%

Period High

$34.37

Period Low

$14.95

Latest

$29.10

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Alumis Inc. Common Stock

NASDAQ:ALMS

$2.98B

Solid Biosciences Inc.

NASDAQ:SLDB

$556.28M

PureTech Health plc

NASDAQ:PRTC

$424.07M

Autolus Therapeutics plc

NASDAQ:AUTL

$415.18M

Ocugen, Inc.

NASDAQ:OCGN

$409.61M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

$316.61M

Benitec Biopharma Inc.

NASDAQ:BNTC

$293.44M

Quantum-Si incorporated

NASDAQ:QSI

$187.28M

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

$186.68M

ADC Therapeutics S.A.

NYSE:ADCT

$133.55M

What is the latest NGNE filing?

The latest filing shown is 8-K dated Jun 8, 2026.

How many recent filings does NGNE have?

Intrinsic Alpha currently shows 20 recent filings for NGNE.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.